Severe rhabdomyolysis induced renal failure after influenza vaccination in a patient on statins therapy

Introduction: There are various causes leading to acute rhabdomyolysis, and the most common potentially lethal complication of rhabdomyolysis is acute kidney injury. Influenza vaccination-associated rhabdomyolysis with acute renal failure is rarely reported in literature. There are few data regarding kidney biopsy results from rhabdomyolysis induced renal failure after influenza vaccination. Case Report: A 55-year-old male with chronic kidney disease stage 3a with hyperlipidemia under rosuvastatin control, who was admitted due to severe rhabdomyolysis induced renal failure after influenza vaccination. Kidney biopsy revealed acute tubular necrosis (ATN) and acute interstitial nephritis (AIN) superimposed on focal segmental glomerulosclerosis. Conclusion: Our experience illustrates the dual pathologic findings of ATN and AIN, both induced by influenza vaccine in a patient with chronic kidney disease on statin therapy. (This page in not part of the published article.) International Journal of Case Reports and Images, Vol. 8 No. 3, March 2017. ISSN – [0976-3198] Int J Case Rep Images 2017;8(3):205–208. www.ijcasereportsandimages.com Chen et al. 205 CASE REPORT PEER REVIEWED | OPEN ACCESS Severe rhabdomyolysis induced renal failure after influenza vaccination in a patient on statins therapy Shu-Hua Chen, Cheng-Jui Lin, Tung-Ying Chen


INTRODUCTION
There are several causes of rhabdomyolysis, including trauma, exertion, lipid-lowering agents, infection, electrolyte imbalance and toxins. Injury of skeletal muscle leads to release of intramuscular contents, including creatine phosphokinase and myoglobin, often resulting in acute kidney injury. Acute kidney injury secondary to rhabdomyolysis is fairly common, representing about 13-50% of all cases of rhabdomyolysis [1][2][3]. There are few reports of influenza vaccination-induced rhabdomyolysis in patients under treatment with lipid-lowering agents. Our report presented a patient, whom had chronic kidney disease and hyperlipidemia under statin therapy, developed severe rhabdomyolysis after an influenza vaccination.

CASE REPORT
A 55-year-old male with history of chronic kidney disease stage 3a and hyperlipidemia with baseline creatinine 1.5 mg/dL two years ago. He was admitted to our hospital with symptoms of severe muscle pain and weakness. He took rosuvastatin 5 mg per day for hyperlipidemia for over one year. The patient received trivalent influenza vaccine (Sanofi Pasteur) five days prior to admission. He suffered from a single episode of fever and several times of diarrhea on the following four days. Subsequently, he developed general muscle soreness and weakness.
After admission, rosuvastatin was discontinued. He was treated with aggressive intravenous fluid supplement and sodium bicarbonate alkalization therapy. Serum creatine kinase rose to a peak level of 77075 IU/L on the third day of admission (Figure 1). Urine myoglobin test was positive on the sixth day of admission. Concurrently, deterioration of renal function was noted (highest serum creatinine 12.2 mg/dL on 12th day of admission) and oliguria (daily urine amount < 200 ml) was noted as well ( Figure 2). Temporary hemodialysis was total of six sessions between 3rd day and 14th day of admission. The level of serum creatine kinase and creatinine decreased gradually on the following days with intensive treatment. Renal biopsy was performed on the 17th day of admission, when daily urine amount was more than 2 liters. Histopathology, revealed the presence of advanced focal segmental glomerulosclerosis (FSGS) (Figure 3), acute tubular necrosis (ATN) ( Figure 4) and allergyassociated acute interstitial nephritis (AIN) ( Figure 5). Serum creatinine was 2.3 mg/dL on the 52th day.

DISCUSSION
Seasonal influenza vaccine contains inactivated viruses and is administered annually to protect against the influenza. According to Taiwan Centers for Disease Control and Prevention vaccination guidelines, influenza vaccines are recommended for everyone ages six months and older. Trivalent influenza vaccines protect against   two influenza A strains, H1N1 and H3N2, and one influenza B strain. Mild side effects from the influenza vaccination include transient soreness, redness or swelling at the injection site, nausea, low-grade fever and headache. Rare but serious side effects were anaphylactic shock, difficult breathing, swelling around the eyes or lips, wheal, temporary thrombocytopenia, high fever and neurologic symptoms, such as Guillain-Barre syndrome [4].
In addition to lipid-lowering agents and virus infection, there are several reports about rhabdomyolysis triggered by seasonal influenza vaccination [5][6][7][8][9]. Raman et al. found the first report of acute renal failure secondary to rhabdomyolysis following an influenza vaccination in a renal transplant recipient who had been on simvastatin and cyclosporine A therapy [5]. Novati et al. presented one case on statin therapy with acute renal failure twelve days after influenza vaccination, which consisted with acute tubulointerstitial nephropathy on urine analysis [9]. From our report, this patient developed severe rhabdomyolysis and acute allergic reactions with influenza vaccination. The renal pathological findings also demonstrated FSGS, ATN and AIN. The cause of rhabdomyolysis includes statin therapy as well as influenza vaccination. Statin may exert toxic effects on skeletal muscle, but whose overall incidence is typically <0.1% of patients receiving statin therapy [10]. Despite the widespread use of statin, the mechanism of statin-induced myopathy remains controversial and poorly understood. We know that, the ubiquitinproteasome-dependent proteolytic pathway (UP pathway) is responsible for the breakdown of long-lived myofibrillar proteins (e.g., actin, myosin and troponin) in skeletal muscle, which releases of myoglobin. Statin may upregulate skeletal muscle gene expression of UP pathway [11]. Mechanisms of rhabdomyolysis induced acute kidney injury are renal vasoconstriction secondary to excessive leakage of extracellular fluid into the damaged muscle cells, formation of intratubular myoglobin casts that induce intra-tubular obstruction and direct toxin-related tubular damage [12]. In this case, no myoglobin cast was found in renal tubules on renal biopsy, which could be disappearing of myoglobin cast on the recovery of oliguria. Moreover, this patient had a previous history of chronic kidney disease (CKD) stage 3a, and was diagnosed as focal segmental glomerulosclerosis (FSGS) by kidney pathology. This can explain the patient's susceptibility for developing rhabdomyolysis induced renal failure after vaccination. Acute interstitial nephritis is often associated with use of drugs or infection, and is likely mediated through allergic mechanisms. In this patient, influenza vaccination may explain this hypersensitivity reaction. Although, influenza vaccination-associated rhabdomyolysis is rare, our report provides clinician a warning about serious complication in patients with renal impairment and statin therapy, that intend to be vaccinated against common viruses.

CONCLUSION
In summary, rhabdomyolysis induced renal failure may contribute to the morbidity and mortality during hospitalization. We report a case developing severe rhabdomyolysis-induced renal failure with dual pathologic finding after an influenza vaccination. Kidney pathology demonstrates that acute tubular necrosis and

AN INTRODUCTION
Edorium Journals: On Web

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Edorium Journals: An introduction
Edorium Journals Team

But why should you publish with Edorium Journals?
In less than 10 words -we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle. Something more...
We request you to have a look at our website to know more about us and our services.
We welcome you to interact with us, share with us, join us and of course publish with us.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.* This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services. * Terms and condition apply. Please see Edorium Journals website for more information.